Locus Biosciences

Locus Biosciences

Locus Biosciences is a biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products.

Locus Biosciences is a biotechnology company headquartered in Raleigh, North Carolina and was founded in 2015 by Charles Gersbach, Chase Beisel, Dave Ousterout, Nick Taylor, Paul Garofolo, and Rodolphe Barrangou.

Locus Biosciences develops CRISPR-engineered phage therapeutics, and uses Type I CRISPR-Cas3 system to destroy the DNA of target bacteria cells. Locus is the exclusive global licensee of the foundational CRISPR-Cas3 patent estate from North Carolina State University and Duke University. Although CRISPR-Cas9 is being used by a variety of companies to treat human diseases, Locus is the only company using CRISPR-Cas3 to tackle the problem of multidrug-resistant bacteria.

Locus's CRISPR-Cas3-engineered phage ("crPhage") platform is notable because it combines the safety profile of phages with the efficacy advantage of CRISPR. crPhage products kill target bacteria, including antibiotic-resistant superbugs, while leaving the many species of good bacteria in the body unharmed. The acquisition of EpiBiome's automation platform helps Locus develop these crPhage products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome more rapidly.

Funding
Series A

On November 14, 2017 Locus Biosciences completed their series A funding round with $19 million in funding from Artis Ventures (lead investor), Starlight Ventures, North Carolina Biotechnology Center, and Abstract Ventures.

Timeline

July 17, 2018
Acquisition of phage discovery platform

Locus Biosciences announced its acquisition of EpiBiome's high-throughput bacteriophage ("phage") discovery platform.

November 14, 2017
Series A - $19m

Locus closed $19m in series A funding. Led by Artis Ventures with backup from Tencent Holdings, Abstract Ventures and the North Carolina Biotechnology Centre, the first round fundraising is intended to fund through an IND filing and first clinical trial.

2015
Locus Biosciences was founded by Charles Gersbach, Chase Beisel, Dave Ousterout, Nick Taylor, Paul Garofolo and Rodolphe Barrangou.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Locus Biosciences Series A Funding Round July 2018
7,000,000
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Dave Ousterout

Co-founder, CTO

Paul Garofolo

Co-founder, CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Sophie Burkholder
March 8, 2021
TechCrunch
Antibiotic resistance is one of the biggest potential threats to global health today. But Locus Biosciences is hoping that their crPhage technology might provide a new solution. Based in North Carolina's Research Triangle, the startup recently announced promising phase 1b clinical trial results for their use of CRISPR-Cas3-enhanced bacteriophages as a treatment for urinary tract [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.